Further Expand Pipelines for Medical Aesthetic Products
Sun Moral International (HK) Limited (“Sun Moral International”), a subsidiary of the Company, has entered into an acquisition agreement with the original shareholder (the “Seller”) of the American company Genesis Biosystems, Inc. (“Genesis”) on 28 December 2021, and both parties agreed that the entire equity of Genesis is to be acquired by Sun Moral International.
Founded in 2001, the American company Genesis is a manufacturer of high-quality aesthetics and biomedical products, and mainly engages in the development, manufacture and distribution of aesthetic equipment, focusing on the microchannel system and fat collection products for beauty treatments, skincare as well as plastic surgery.
Genesis’ microchannel system products include Derma Genesis® , Dermacel® , DermaFrac™ and other series of products, which can enter into the skin through a thin and tiny microneedle and create minute pore channel well-distributed on the skin via vacuum suction. The minor pinprick does not cause bleeding of the skin or side effects, with no convalescence needed.
Genesis’ LipiVage® fat collection system is an innovative product with independent and ready-touse two-step fat collecting, cleaning and transferal system, which is easy to operate and has mild effects. It is safe and convenient as an equipment with aseptic packaging, and is the improved version of the conventional negative pressure liposuction technology.
In June 2021, Meiyen Laboratory Inc, an American subsidiary of the Group, has entered into a strategic cooperation with Genesis in relation to the product, and obtained the exclusive distribution right for it in Greater China and South Korea. The Group will continue to use global resources to introduce world-class and technologically advanced medical aesthetic products into China, and promote the efficient progress and rapid development of China's medical aesthetic industry.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group said: “The Acquisition is expected to further expand the Group’s pipelines for medical aesthetic products, consolidate the comprehensive layout in the non-surgical and surgical medical aesthetic fields and further accelerate the procedure for its enterprise development of the Group’s medical aesthetic business from product distribution to an integrated platform.”
MeiYan KongJian
Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries the “Group”) (HKSE: 00460.HK) is focusing on the high-growth and low penetration PRC medical aesthetics market, MeiYan KongJian, the Group’s medical aesthetics platform, is dedicated to building a leading company featuring with full medical aesthetics product matrix by leveraging the rigour and innovation of pharmaceutical companies. The Group entered into an exclusive distribution agreement with Hugel in the South Korean in relation to botulinum toxin and hyaluronic acid product in 2014, which marked the layout forming in the medical aesthetics field. After years of development, the Group has not only formed a product matrix with tens of “self-development + BD” products, but also established a R&D center, the Meiyen Laboratory, in the U.S., and completed the construction of three manufacturing bases with high efficiency and low cost. As a “one-stop” new medical aesthetics platform focusing on the PRC market, MeiYan KongJian is estimated to achieve the strategic objective of building an international and leading medical aesthetics company through globalized layout and localized production, comprehensive and professional product matrix, strong R&D and registration capabilities as well as diversified marketing ability and comprehensive channel coverage.
Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001 and listed on the Main Board of the Hong Kong Stock Exchange Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries the “Group”) (HKSE: 00460.HK) is an international pharmaceutical company led and driven by both innovation and generic, with an independent and leading independent research and development (“R&D”) technology platform, a rich global product pipeline and a mature and excellent sales system. Focusing on high-growth therapeutic areas such as oncology, metabolic diseases, medical aesthetics, anti-infectives, digestive system, cardiovascular and cerebrovascular, Sihuan Pharmaceutical is building a leading medical aesthetic and biopharmaceutical leader in China with a two-wheel drive strategy of independent innovation and research and incubation to cultivate high growth new businesses.